iotrolan (osmovist) Report issue

Small molecule Approved FDA
ChEMBL Drug Central Drugs@FDA KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Iotrol, a nonionic dimeric, intrathecal contrast medium for myelography. This agent does not exhibit any cytotoxic effect on human healthy nucleus pulposus (NP) cells.   NCATS

Chemistry

  • SMILES: CN(C(=O)CC(=O)N(C)C1=C(I)C(C(=O)NC(CO)C(O)CO)=C(I)C(C(=O)NC(CO)C(O)CO)=C1I)C2=C(I)C(C(=O)NC(CO)C(O)CO)=C(I)C(C(=O)NC(CO)C(O)CO)=C2I
  • InChIKey: XUHXFSYUBXNTHU-UHFFFAOYSA-N
  • Mol. Mass: 1626.2332
  • ALogP: Missing data
  • ChEMBL Molecule:
    iotrolan  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Discontinued
  • Delivery Methods: Parenteral
  • Pro Drug: No

Alternative names

1,3-benzenedicarboxamide, 5,5'-((1,3-dioxo-1,3-propanediyl)bis(methylimino))bis(n,n'-bis(2,3-dihydroxy-1-(hydroxymethyl)propyl))-2,4,6-triiodo- | berlex brand of iotrolan | dl 3117 | dl 3-117 | dl-3-117 | iotrol | iotrolan | iotrovist | isovist | isovist 300 | osmovist | osmovist 190 | osmovist 240 | schering brand of iotrolan | zk-39482

Organizations (2)

Research & Development (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (1)

Approved Indications (1)


 

Diagnostic Imaging (approved 1984)

Experimental Indications - Clinical Trial Phases 1-4 (0)

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue